Role of [ 18F]-fluorodeoxy-D-glucose positron emission tomography and computed tomography in the early detection of persistent/recurrent thyroid carcinoma in intermediate-to-high risk patients following initial radioactive iodine ablation therapy

Thyroid

Volumn 22, Issue 2, 2012, Pages 157-164

  Kim, Min Hee ^a   Joo Hyun, O ^a   Ko, Sun Hee ^a   Bae, Ja Seong ^a   Lim, Dong Jun ^a   Kim, Sung Hoon ^a   Baek, Ki Hyun ^a   Lee, Jong Min ^a   Kang, Moo Il ^a   Cha, Bong Yun ^a   Lee, Kwang Woo ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOACTIVE IODINE; THYROGLOBULIN;

ADULT; ARTICLE; CANCER RECURRENCE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DRUG MEGADOSE; ECHOGRAPHY; FEMALE; HIGH RISK PATIENT; HUMAN; INTERMEDIATE RISK PATIENT; MAJOR CLINICAL STUDY; MALE; PATIENT; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK; SENSITIVITY AND SPECIFICITY; THYROID CARCINOMA; TUMOR ABLATION;

ADULT; CARCINOMA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; THYROGLOBULIN; THYROID NEOPLASMS;

EID: 84863018634     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2011.0177     Document Type: Article

References (45)

1. Jung KW, Park S, Kong HJ, Won YJ, Boo YK, Shin HR, Park EC, Lee JS 2010 Cancer statistics in Korea: incidence, mortality and survival in 2006-2007. J Korean Med Sci 25:1113-1121.
2. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83:2638-2648. (Pubitemid 29019586)
3. Brierley J, Tsang R, Panzarella T, Bana N 2005 Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years. Clin Endocrinol (Oxf) 63:418-427. (Pubitemid 41442336)
4. Lin JD, Chao TC, Hsueh C, Kuo SF 2009 High recurrent rate of multicentric papillary thyroid carcinoma. Ann Surg Oncol 16:2609-2616.
5. Grant CS, Stulak JM, Thompson GB, Richards ML, Reading CC, Hay ID 2010 Risks and adequacy of an optimized surgical approach to the primary surgical management of papillary thyroid carcinoma treated during 1999-2006. World J Surg 34:1239-1246.
6. Woodrum DT, Gauger PG 2005 Role of 131I in the treatment of well differentiated thyroid cancer. J Surg Oncol 89:114-121. (Pubitemid 40315907)
7. Lin JD, Hsueh C, Chao TC 2009 Early recurrence of papillary and follicular thyroid carcinoma predicts a worse outcome. Thyroid 19:1053-1059.
8. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
9. Kidd EA, Siegel BA, Dehdashti F, Grigsby PW 2007 The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer 110:1738-1744. (Pubitemid 47557298)
10. Kornberg A, Freesmeyer M, Barthel E, Jandt K, Katenkamp K, Steenbeck J, Sappler A, Habrecht O, Gottschild D, Sett-macher U 2009 18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant 9:592-600.
11. Kidd EA, Siegel BA, Dehdashti F, Grigsby PW 2010 Pelvic lymph node F-18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer. Cancer 116:1469-1475.
12. Chung JK, So Y, Lee JS, Choi CW, Lim SM, Lee DS, Hong SW, Youn YK, Lee MC, Cho BY 1999 Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. J Nucl Med 40:986-992. (Pubitemid 29269219)
13. Muros MA, Llamas-Elvira JM, Ramirez-Navarro A, Gomez MJ, Rodriguez-Fernandez A, Muros T, Lopez de la Torre M, Becerra A, Carreras JL 2000 Utility of fluorine-18-fluoro-deoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels. Am J Surg 179:457-461.
14. Lim D-J, O JH, Kim M-H, Kim J-H, Kwon H-S, Kim S-H, Kang M-I, Cha B-Y, Lee K-W, Son H-Y 2010 Clinical significance of observation without repeated radioiodine therapy in differentiated thyroid carcinoma patients with positive surveillance whole-body scans and negative thyro-globulin. Korean J Intern Med 25:408-414.
15. Leboulleux S, Girard E, Rose M, Travagli JP, Sabbah N, Caillou B, Hartl DM, Lassau N, Baudin E, Schlumberger M 2007 Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer. J Clin Endocrinol Metab 92:3590-3594. (Pubitemid 47435339)
16. Mazzaferri EL, Kloos RT 2001 Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86:1447-1463. (Pubitemid 32374886)
17. Frasoldati A, Pesenti M, Gallo M, Caroggio A, Salvo D, Valcavi R 2003 Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer 97:90-96. (Pubitemid 36033867)
18. Torlontano M, Attard M, Crocetti U, Tumino S, Bruno R, Costante G, D'Azzo G, Meringolo D, Ferretti E, Sacco R, Arturi F, Filetti S 2004 Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab 89:3402-3407. (Pubitemid 38951911)
19. Clark OH, Hoelting T 1994 Management of patients with differentiated thyroid cancer who have positive serum thy-roglobulin levels and negative radioiodine scans. Thyroid 4:501-505.
20. Iagaru A, Kalinyak JE, McDougall IR 2007 F-18 FDG PET/CT in the management of thyroid cancer. Clin Nucl Med 32:690-695. (Pubitemid 47294862)
21. Larson SM, Robbins R 2002 Positron emission tomography in thyroid cancer management. Semin Roentgenol 37:169-174. (Pubitemid 34764846)
22. Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, Tuttle RM, Drucker W, Larson SM 2006 Real-time prognosis for metastatic thyroid carcinoma based on 2-18Ffluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91:498-505. (Pubitemid 43236915)
23. Frilling A, Tecklenborg K, Gorges R, Weber F, Clausen M, Broelsch EC 2001 Preoperative diagnostic value of (18)F fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg 234:804-811. (Pubitemid 33117201)
24. Yun M, Noh TW, Cho A, Choi YJ, Hong SW, Park CS, Lee JD, Kim CK Visually discernible 18Ffluorodeoxyglucose uptake in papillary thyroid microcarcinoma: a potential new risk factor. J Clin Endocrinol Metab 95:3182-3188.
25. Alzahrani AS, Abouzied ME, Salam SA, Mohamed G, Rifai A, Al Sugair A, Amin T 2008 The role of F-18-fluorodeoxy-glucose positron emission tomography in the postoperative evaluation of differentiated thyroid cancer. Eur J Endocrinol 158:683-689. (Pubitemid 351639606)
26. Jeong HS, Baek CH, Son YI, Choi JY, Kim HJ, Ko YH, Chung JH, Baek HJ 2006 Integrated 18F-FDG PET/CT for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma: comparison with ultrasound and contrast-enhanced CT. Clin Endocrinol (Oxf) 65:402-407.
27. Shammas A, Degirmenci B, Mountz JM, McCook BM, Branstetter B, Bencherif B, Joyce JM, Carty SE, Kuffner HA, Avril N 2007 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med 48:221-226. (Pubitemid 47555347)
28. Kaneko K, Abe K, Baba S, Isoda T, Yabuuchi H, Sasaki M, Hatakenaka M, Honda H 2010 Detection of residual lymph node metastases in high-risk papillary thyroid cancer patients receiving adjuvant I-131 therapy: the usefulness of F-18 FDG PET/CT. Clin Nucl Med 35:6-11.
29. Miller ME, Chen Q, Elashoff D, Abemayor E, St John M 2010 Positron emission tomography and positron emission to-mography-CT evaluation for recurrent papillary thyroid carcinoma: meta-analysis and literature review. Head Neck 33:562-565.
30. Hwang HS, Perez DA, Orloff LA 2009 Comparison of positron emission tomography/computed tomography imaging and ultrasound in staging and surveillance of head and neck and thyroid cancer. Laryngoscope 119:1958-1965.
31. Schluter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M 2001 Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thy-roglobulin and negative 131I scan. J Nucl Med 42:71-76. (Pubitemid 32104780)
32. Seo JH, Lee SW, Ahn BC, Lee J 2010 Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using (18)F-FDG PET/CT. Clin Endocrinol (Oxf) 72:558-563.
33. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A 2002 Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have un-detectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 87:1499-1501. (Pubitemid 34615228)
34. Kim WG, Ryu JS, Kim EY, Lee JH, Baek JH, Yoon JH, Hong SJ, Kim ES, Kim TY, Kim WB, Shong YK 2010 Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxy-glucose positron emission tomography scan. J Clin En-docrinol Metab 95:1169-1173.
35. Leboulleux S, Schroeder PR, Busaidy NL, Auperin A, Cor-one C, Jacene HA, Ewertz ME, Bournaud C, Wahl RL, Sherman SI, Ladenson PW, Schlumberger M 2009 Assessment of the incremental value of recombinant thyrotropin stimulation before 2-18F-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin En-docrinol Metab 94:1310-1316.
36. Greven KM, Williams DW 3rd, Keyes JW Jr, McGuirt WF, Watson NE Jr, Randall ME, Raben M, Geisinger KR, Cap-pellari JO 1994 Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer 74:1355-1359. (Pubitemid 24301792)
37. Greven KM, Williams DW 3rd, McGuirt WF Sr, Harkness BA, D'Agostino RB Jr, Keyes JW Jr, Watson NE Jr 2001 Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 23:942-946. (Pubitemid 32977536)
38. Ryan WR, Fee WE Jr, Le QT, Pinto HA 2005 Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope 115:645-650. (Pubitemid 40530014)
39. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A Estimating risk of recurrence in differentiated thyroid cancer after total thy-roidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20:1341-1349.
40. Brassard M, Borget I, Edet-Sanson A, Giraudet AL, Mundler O, Toubeau M, Bonichon F, Borson-Chazot F, Leenhardt L, Schvartz C, Dejax C, Brenot-Rossi I, Toubert ME, Torlontano M, Benhamou E, Schlumberger M 2011 Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J Clin Endocrinol Metab 96:1352-1359.
41. Gould MK, Kuschner WG, Rydzak CE, Maclean CC, Demas AN, Shigemitsu H, Chan JK, Owens DK 2003 Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med 139:879-892.
42. Chen L, Luo Q, Shen Y, Yu Y, Yuan Z, Lu H, Zhu R 2008 Incremental value of 131I SPECT/CT in the management of patients with differentiated thyroid carcinoma. J Nucl Med 49:1952-1957.
43. Wong KK, Zarzhevsky N, Cahill JM, Frey KA, Avram AM 2009 Hybrid SPECT-CT and PET-CT imaging of differentiated thyroid carcinoma. Br J Radiol 82:860-876.
44. Grewal RK, Tuttle RM, Fox J, Borkar S, Chou JF, Gonen M, Strauss HW, Larson SM, Schoder H 2010 The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer. J Nucl Med 51:1361-1367.
45. Wang W, Larson SM, Tuttle RM, Kalaigian H, Kolbert K, Sonenberg M, Robbins RJ 2001 Resistance of 18f-fluoro-deoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid 11: 1169-1175. (Pubitemid 34041898)